在患有慢性炎症性眼病的患者中,补充药物的坚持
Arthi D Bharadwaj1, Avisek Datta2, Pooja Bhat1
1Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA.
Ocular immunology and inflammation
|November 25, 2024
概括
药房补充数据显示,在炎症性眼病 (IED) 中,免疫抑制疗法 (IMT) 的坚持率低 (63.9%). 不坚持,特别是在多种药物治疗时,会影响治疗的有效性,尽管大多数患者能够控制疾病.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 非传染性炎症性眼病 (IED) 需要长期免疫抑制疗法 (IMT).
- 评估患者对IMT的坚持对于有效的疾病管理和预防并发症至关重要.
- 药房分发提供了一个潜在的客观措施来跟踪IMT遵守.
研究的目的:
- 用药房分发的IED患者数据来评估IMT的坚持率.
- 为了确定坚持对眼部疾病控制的影响.
- 识别与不遵守相关的因素,并比较医疗记录和药房记录之间的遵守数据.
主要方法:
- 对IED患者的回顾性图表审查至少持续两年.
- 通过医疗记录审查 (预约/实验室出席,提供者笔记) 和药房补充数据来评估遵守.
- 通过临床检查结果评估的疾病控制.
主要成果:
- 研究了63名患者的队列,根据药房数据,平均坚持率为63.9%.
- 超过三分之二的患者 (67.2%) 的平均坚持率低于85%,表明不坚持.
- 在接受多次IMT的患者中,不坚持是显著更高的 (4.72倍).
- 在大多数患者 (86.2%) 中,可以控制眼部炎症.
- 来自医疗记录和药房记录的遵守数据显示,在71.6%的病例中,一致性.
结论:
- 通过药房数据评估的IED患者对IMT的坚持往往是不理想的,特别是那些服用多种药物的患者.
- 尽管面临坚持的挑战,但大多数患者都能实现良好的眼部疾病控制.
- 与医疗记录信息相比,药房分发数据是评估遵守的可靠相关值.
相关概念视频
01:27Open Angle Glaucoma: Treatment
393
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
393
01:29Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:22Drug Delivery: Miscellaneous Routes
328
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
328